Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (Zavegepant*) Intranasal (IN) for the Acute Treatment of Migraine

NCT04408794 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04408794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04408794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (Zavegepant*) Intranasal (IN) for the Acute Treatment of Migraine
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
June 29, 2020
Completion date
December 23, 2021
Enrollment
974 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

acute migraine